Burden of Prostate Cancer in China, 1990–2019: Findings From the 2019 Global Burden of Disease Study

25Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Our study is the first to illustrate the age and geographic distribution differences in the epidemiology of prostate cancer from 1990 to 2019 in China. Prostate cancer (PC) is a malignant tumor derived from prostate epithelial cells and is one of the most commonly diagnosed cancers in men. In recent years, the global incidence and the annual deaths number of PC showed a continuous increase, which has caused a huge disease burden on human health. In terms of the global average, the incidence and mortality of PC in China are relatively low. However, the age-standardized incidence rate of PC was 17.3/100,000 in 2019 in China, with a 95.2% rise compared to 1990, while the global growth rate of incidence rate over the same period is 13.2%. This showed that the development trend of PC in China is not optimistic. There are few precise studies on the epidemiology of PC in China. After the general analysis strategy used in the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019, we elaborated on the incidence, mortality, and disability-adjusted life-years (DALYs) and the corresponding age-standardized rate of the Chinese PC population from 1990 to 2019 according to different ages and provinces. We used joinpoint regression analysis to estimate the incidence and mortality trends. Our analysis shows that elderly people over 80 are still the main focus of incidence and death. The epidemiology and disease burden of PC of different provinces in China show obvious regional differences, and some certain provinces such as HongKong, Macao, and Zhejiang should be paid more attention. More targeted and effective strategies should be developed to reduce the burden of PC in China.

References Powered by Scopus

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

66847Citations
N/AReaders
Get full text

A novel coronavirus from patients with pneumonia in China, 2019

20072Citations
N/AReaders
Get full text

Cancer statistics in China, 2015

16880Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice

17Citations
N/AReaders
Get full text

Trends of Prostate Cancer Morbidity in Low-Incidence Countries from 1990–2019

5Citations
N/AReaders
Get full text

Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, F., Wang, C., Xia, H., Lin, Y., Zhang, D., Yin, P., & Yao, S. (2022). Burden of Prostate Cancer in China, 1990–2019: Findings From the 2019 Global Burden of Disease Study. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.853623

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

40%

Professor / Associate Prof. 1

20%

Lecturer / Post doc 1

20%

Researcher 1

20%

Readers' Discipline

Tooltip

Social Sciences 1

25%

Medicine and Dentistry 1

25%

Veterinary Science and Veterinary Medic... 1

25%

Psychology 1

25%

Save time finding and organizing research with Mendeley

Sign up for free